<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00689611</url>
  </required_header>
  <id_info>
    <org_study_id>ZESCA 9197</org_study_id>
    <secondary_id>ISRCTN75356261</secondary_id>
    <nct_id>NCT00689611</nct_id>
  </id_info>
  <brief_title>Zyban as an Effective Smoking Cessation Aid for Patients Following an Acute Coronary Syndrome: The ZESCA Trial</brief_title>
  <acronym>ZESCA</acronym>
  <official_title>Zyban as an Effective Smoking Cessation Aid for Patients Following an Acute Coronary Syndrome: The ZESCA Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mark Eisenberg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canadian Institutes of Health Research (CIHR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Heart and Stroke Foundation of Canada</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>McGill University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients who continue to smoke after a heart attack have a 35% increased risk of a recurrent
      event or death compared with those who quit. Many patients attempt to stop smoking after a
      heart attack, but relapse rates approach 66%. A variety of smoking cessation aids have been
      shown to be effective for the general population. However, bupropion is the only non-nicotine
      replacement therapy shown to improve abstinence rates in healthy young smokers. Furthermore,
      nicotine replacement therapies (NRTs) are contraindicated in the immediate period following a
      heart attack because of the undesirable effects of nicotine. Although bupropion has been
      successfully used to reduce smoking rates in healthy young populations, its efficacy and
      safety in the setting of patients recovering from an ACS is unknown. These patients, if they
      continue to smoke, are at exceptionally high risk for recurrent cardiac events. If bupropion
      is effective in this population, it will have a major impact on secondary prevention of
      recurrent clinical events in patients who suffer a heart attack.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients who continue smoking after ACS have a 35% increased risk of reinfarction or death
      compared with those who quit. Many patients attempt to stop smoking after an acute coronary
      syndrome (ACS), but relapse rates approach 66%. A variety of smoking cessation aids have been
      shown to be effective for the general population. However, physicians are reluctant to use a
      nicotine-based therapy because of its hemodynamic effects. Bupropion is the only non-nicotine
      replacement therapy shown to improve abstinence rates in healthy young smokers by
      approximately 50%. Although bupropion has successfully been used to reduce smoking rates in
      healthy young populations, its efficacy and safety in the setting of patients recovering from
      an ACS is unknown.

      The ZESCA Trial will directly compare the efficacy and safety of bupropion versus placebo as
      a means of reducing smoking rates in patients following an ACS. The ZESCA Trial will be a
      multi-center effort, coordinated from the Jewish General Hospital/McGill University
      (Montreal, Quebec). A total of 1500 patients will be randomized following an ACS but before
      hospital discharge via an Internet web site. Prior to the start of the treatment, patients in
      both treatment arms will receive a standard physician-administered counseling session
      regarding smoking cessation. Patients will begin treatment in-hospital and will be monitored
      in-hospital for ≥ 2 days prior to discharge. Half the patients will receive bupropion for 9
      weeks and the other half will receive placebo pills for 9 weeks. Patients receiving bupropion
      will take 150 mg once per day for 3 days and then 150 mg twice per day for the remainder of 9
      weeks. Prior to discharge, the patients will receive an information sheet listing the
      possible side effects of bupropion. They will be advised to consult the treating physician
      should they experience any listed side effects. While in-hospital, patients will have quit
      smoking and they will be instructed to not restart smoking when discharged. Phone calls to
      the patients will be made by the study nurses at weeks 1 and 2 of the 9-week treatment
      period. In addition, the patients will have clinic visits at weeks 4 and 9 as well as months
      6 and 12. Smoking abstinence will be assessed at 4 weeks, 9 weeks, 6 months, and 12 months
      after randomization. Smoking abstinence will be defined as the complete abstinence in the
      week prior to the clinic visits and levels of exhaled carbon monoxide ≤ 10 ppm. Side effects
      of bupropion in patients following ACS as well as clinical events following initiation of
      treatment will be measured at weeks 1-8 (by telephone calls), and weeks 4 and 9 as well as
      months 6 and 12 (by clinic visits). Withdrawal symptoms will also be assessed by the nurses
      during their weekly calls.

      Trials previously conducted with bupropion involved young healthy smokers. The ZESCA trial
      will be the first to examine the utility of bupropion in a group of patients with an ACS.
      These patients, if they continue to smoke, are at exceptionally high risk for recurrent
      cardiac events. If bupropion is effective in this population, it will have a major impact on
      secondary prevention of recurrent clinical events in patients who suffer an ACS.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2005</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Smoking Abstinence</measure>
    <time_frame>12 months</time_frame>
    <description>The primary end point was 7-day point prevalence smoking abstinence at 12 months. Smoking cessation was defined as self-reported abstinence in the week before the 12-month clinic visit and a measurement of exhaled carbon monoxide less than 11 ppm.
The primary end point was analyzed on an intention-to-treat (ITT) basis. Our ITT analysis assumed that those who withdrew consent or were lost to follow-up had returned to smoking at their baseline rates. This assumption is common in smoking cessation trials.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Composite Major Adverse Cardiovascular Events (MACE)</measure>
    <time_frame>12 months</time_frame>
    <description>All clinical end points were adjudicated by members of the Endpoints Evaluation Committee who were blinded to treatment assignment.
Composite MACE (death, myocardial infarction, unstable angina)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">392</enrollment>
  <condition>Acute Coronary Syndrome</condition>
  <condition>Myocardial Infarction</condition>
  <condition>Smoking</condition>
  <arm_group>
    <arm_group_label>P</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Half of patients will receive placebo for 9 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Half of patients will receive bupropion for 9 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupropion HCl ER</intervention_name>
    <description>150 mg tablets po qd for 3 days and then 150 mg po bid for remainder of 9 weeks</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Zyban</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>P</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ≥ 18 years of age

          -  Smoke at least 10 cigarettes/day for the past year

          -  Suffered an enzyme-positive ACS

          -  Planned hospitalization of ≥24 hours

          -  Motivated to quit smoking

          -  Likely to be available for follow-up

          -  Able to understand and read English or French

        Exclusion Criteria:

          -  Medical condition with a prognosis of &lt; 1 year

          -  Pregnant or lactating

          -  Current use of Wellbutrin or any other medications that contain bupropion

          -  Current use of any medical therapy for smoking cessation (e.g. BuSpar, fluoxetine,
             doxepin, nicotine gum, or nicotine patch)

          -  Current seizure disorder, history of seizures or predisposition to seizures (e.g.
             history of brain tumor, severe head trauma, or stroke)

          -  History of bulimia or anorexia nervosa

          -  Current diagnosis of major depression (requiring medication), bipolar disease, or
             dementia

          -  History of suicidal events (previous suicide attempt, suicidal ideation) or family
             history of suicide

          -  Diagnosed hepatic failure, cirrhosis, hepatitis or history of hepatic impairment (AST
             or ALT levels ≥ 2 times upper limit of normal prior to admission for ACS)

          -  Renal impairment with creatinine levels ≥ 2 times the upper limit of normal

          -  Excessive alcohol consumption defined as ≥ 14 alcoholic drinks per week

          -  Use of any illegal drugs in the past year (e.g. cocaine, heroin, opiates)

          -  Current use of medications that lower seizure threshold e.g. amantadine,
             anti-depressants, anti-malarials, anti-psychotics, levodopa, lithium, quinolone
             antibiotics, ritonavir, systemic steroids, theophyllin, type 1C antiarrhythmics (e.g.
             encainide, flecainide, propafenone)

          -  Use of MAO inhibitors or thioridazine in the past 15 days

          -  Current use of over-the-counter stimulants (e.g. ephedrine, phenylephrine) or
             anoretics
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark J Eisenberg, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jewish General Hospital/ McGill University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Parkview Medcial Center</name>
      <address>
        <city>Pueblo</city>
        <state>Colorado</state>
        <zip>81003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Maine Medical Center</name>
      <address>
        <city>Lewiston</city>
        <state>Maine</state>
        <zip>04240</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bay Regional Medical Center</name>
      <address>
        <city>Bay City</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bassett Healthcare</name>
      <address>
        <city>Cooperstown</city>
        <state>New York</state>
        <zip>13326</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>United Health Services</name>
      <address>
        <city>Johnson City</city>
        <state>New York</state>
        <zip>13790</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stony Brook Hospital and Medical Center</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794-8167</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Schuster Cardiology</name>
      <address>
        <city>Kettering</city>
        <state>Ohio</state>
        <zip>45429</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southwest Cardiology</name>
      <address>
        <city>Kettering</city>
        <state>Ohio</state>
        <zip>45429</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DVA Medical Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Cardiology Specialists</name>
      <address>
        <city>Scranton</city>
        <state>Pennsylvania</state>
        <zip>18501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Riverside Hospital</name>
      <address>
        <city>Newport News</city>
        <state>Virginia</state>
        <zip>23601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charleston Area Medical Center</name>
      <address>
        <city>South Charleston</city>
        <state>West Virginia</state>
        <zip>25309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Heart Foundation of Bangladesh</name>
      <address>
        <city>Dhaka</city>
        <country>Bangladesh</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peter Lougheed Centre of the Calgary General Hospital</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Alberta Hospital</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vancouver Coastal Health</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5M 1L9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Victoria General Hospital</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3T 2E8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Boniface General Hospital</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Brunswick Heart Centre</name>
      <address>
        <city>Saint Johns</city>
        <state>New Brunswick</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valley Regional Hospital</name>
      <address>
        <city>Kentville</city>
        <state>Nova Scotia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ottawa Hospital, General Campus</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Michael's Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital de la Cite de la Sante</name>
      <address>
        <city>Laval</city>
        <state>Quebec</state>
        <zip>H7M 3L9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHA Hotel-Dieu de Levis</name>
      <address>
        <city>Levis</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SMBD- Jewish General Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Sacre-Coeur de Montreal</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hotel-Dieu</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montreal General Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Fleurimont</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CSSS de Sorel-Tracy</name>
      <address>
        <city>Sorel</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CSSS de la Region de Thetford</name>
      <address>
        <city>Thetford Mines</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saskatchewan Drug Research Institute</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7N 0W8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Laval</name>
      <address>
        <city>Quebec</city>
        <zip>G1V 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre for Chronic Disease Control</name>
      <address>
        <city>New Delhi</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isfahan Cardiovascular Research Centre</name>
      <address>
        <city>Isfahan</city>
        <state>Iran</state>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>InterActive Research and Development</name>
      <address>
        <city>Karachi</city>
        <country>Pakistan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital F. Bourguiba</name>
      <address>
        <city>Sousse</city>
        <country>Tunisia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bangladesh</country>
    <country>Canada</country>
    <country>India</country>
    <country>Iran, Islamic Republic of</country>
    <country>Pakistan</country>
    <country>Tunisia</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 30, 2008</study_first_submitted>
  <study_first_submitted_qc>May 30, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2008</study_first_posted>
  <results_first_submitted>December 11, 2013</results_first_submitted>
  <results_first_submitted_qc>April 10, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 23, 2015</results_first_posted>
  <last_update_submitted>April 10, 2015</last_update_submitted>
  <last_update_submitted_qc>April 10, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 23, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>McGill University</investigator_affiliation>
    <investigator_full_name>Mark Eisenberg</investigator_full_name>
    <investigator_title>MD, MPH, Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Acute coronary syndrome</keyword>
  <keyword>Myocardial infarction</keyword>
  <keyword>Smoking cessation</keyword>
  <keyword>Zyban</keyword>
  <keyword>Secondary intervention post-ACS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupropion</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Participants received placebo for 9 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Bupropion</title>
          <description>Participants received bupropion for 9 weeks.
Bupropion HCl ER: 150 mg tablets po qd for 3 days and then 150 mg po bid for remainder of 9 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="200"/>
                <participants group_id="P2" count="192"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="159"/>
                <participants group_id="P2" count="146"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
                <participants group_id="P2" count="46"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All enrolled participants were included in the baseline analyses.</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>participants received placebo for 9 weeks.
Placebo: Placebo</description>
        </group>
        <group group_id="B2">
          <title>Bupropion</title>
          <description>participants received bupropion for 9 weeks.
Bupropion HCl ER: 150 mg tablets po qd for 3 days and then 150 mg po bid for remainder of 9 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="200"/>
            <count group_id="B2" value="192"/>
            <count group_id="B3" value="392"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.4" spread="10.3"/>
                    <measurement group_id="B2" value="54.5" spread="10.4"/>
                    <measurement group_id="B3" value="53.9" spread="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="166"/>
                    <measurement group_id="B2" value="161"/>
                    <measurement group_id="B3" value="327"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pakistan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="101"/>
                    <measurement group_id="B2" value="96"/>
                    <measurement group_id="B3" value="197"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Iran, Islamic Republic of</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tunisia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>India</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>No. of years smoked</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.6" spread="11.9"/>
                    <measurement group_id="B2" value="33.2" spread="13.0"/>
                    <measurement group_id="B3" value="32.9" spread="12.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>No. of cigarettes/day (past year)</title>
          <units>cigarettes/day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23.2" spread="10.4"/>
                    <measurement group_id="B2" value="23.2" spread="10.8"/>
                    <measurement group_id="B3" value="23.2" spread="10.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Index admission was for ST-segment elevation myocardial infarction [STEMI]</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="133"/>
                    <measurement group_id="B2" value="121"/>
                    <measurement group_id="B3" value="254"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cardiac catheterization during index admission</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="136"/>
                    <measurement group_id="B2" value="128"/>
                    <measurement group_id="B3" value="264"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Percutaneous coronary intervention during index admission</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="104"/>
                    <measurement group_id="B2" value="93"/>
                    <measurement group_id="B3" value="197"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Coronary artery bypass graft during index admission</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Smoking Abstinence</title>
        <description>The primary end point was 7-day point prevalence smoking abstinence at 12 months. Smoking cessation was defined as self-reported abstinence in the week before the 12-month clinic visit and a measurement of exhaled carbon monoxide less than 11 ppm.
The primary end point was analyzed on an intention-to-treat (ITT) basis. Our ITT analysis assumed that those who withdrew consent or were lost to follow-up had returned to smoking at their baseline rates. This assumption is common in smoking cessation trials.</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo for 9 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Bupropion</title>
            <description>Participants received bupropion for 9 weeks.
Bupropion HCl ER: 150 mg tablets po qd for 3 days and then 150 mg po bid for remainder of 9 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Smoking Abstinence</title>
          <description>The primary end point was 7-day point prevalence smoking abstinence at 12 months. Smoking cessation was defined as self-reported abstinence in the week before the 12-month clinic visit and a measurement of exhaled carbon monoxide less than 11 ppm.
The primary end point was analyzed on an intention-to-treat (ITT) basis. Our ITT analysis assumed that those who withdrew consent or were lost to follow-up had returned to smoking at their baseline rates. This assumption is common in smoking cessation trials.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="194"/>
                <count group_id="O2" value="183"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.0"/>
                    <measurement group_id="O2" value="37.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Composite Major Adverse Cardiovascular Events (MACE)</title>
        <description>All clinical end points were adjudicated by members of the Endpoints Evaluation Committee who were blinded to treatment assignment.
Composite MACE (death, myocardial infarction, unstable angina)</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo for 9 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Bupropion</title>
            <description>Participants received bupropion for 9 weeks.
Bupropion HCl ER: 150 mg tablets po qd for 3 days and then 150 mg po bid for remainder of 9 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Composite Major Adverse Cardiovascular Events (MACE)</title>
          <description>All clinical end points were adjudicated by members of the Endpoints Evaluation Committee who were blinded to treatment assignment.
Composite MACE (death, myocardial infarction, unstable angina)</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="200"/>
                <count group_id="O2" value="192"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.0"/>
                    <measurement group_id="O2" value="13.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Participants received placebo for 9 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Bupropion</title>
          <description>Participants received bupropion for 9 weeks.
Bupropion HCl ER: 150 mg tablets po qd for 3 days and then 150 mg po bid for remainder of 9 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="200"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial Infarction</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="200"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Unstable Angina</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="200"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <description>Deaths due to: coronary dissection, cardiac arrest (2), multisystem organ failure post-CABG, complications related to duodenal perforation and recurrent septic shock, ischemic event in the bowel or spinal cord.</description>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="200"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Other</sub_title>
                <description>Specific adverse event terms by treatment group are unknown.</description>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="200"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Psychiatric event</sub_title>
                <description>Includes delirium, hallucination, and suicidal ideation</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Stroke</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>4</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="200"/>
                <counts group_id="E2" subjects_affected="58" subjects_at_risk="192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="200"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="18" subjects_affected="18" subjects_at_risk="200"/>
                <counts group_id="E2" events="26" subjects_affected="26" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="200"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="200"/>
                <counts group_id="E2" events="16" subjects_affected="16" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Dream abnormality</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="200"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="200"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="36" subjects_affected="36" subjects_at_risk="200"/>
                <counts group_id="E2" events="43" subjects_affected="43" subjects_at_risk="192"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Relatively high number who withdrew or were lost to follow-up (22.2%), but within expectations for smoking cessation trials; Relatively small numbers of serious adverse events occurred, limiting power to examine secondary safety end points.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Mark J. Eisenberg</name_or_title>
      <organization>Divisions of Cardiology and Clinical Epidemiology, Jewish General Hospital/McGill University</organization>
      <phone>514.340.8222 ext 3564</phone>
      <email>mark.eisenberg@mcgill.ca</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

